Live Breaking News & Updates on விசை குழாய்

Stay updated with breaking news from விசை குழாய். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Global Pancreatic Cancer Opportunity Analysis and Forecasts, 2019-2020 & 2029: CP-613 (devimistat) and TAK-931 (simurosertib) are the Lead Pipeline Candidates in 1L Setting


Share this article
Share this article
ResearchAndMarkets.com s offering.
Pancreatic cancer is currently the fourth leading cause of cancer-related deaths in the United States, following lung cancer and breast cancer and seventh leading cause of cancer related deaths worldwide with 432,242 related deaths being reported in 2018. Pancreatic adenocarcinoma (PDAC), classified as an exocrine pancreatic cancer, is considered to be the most common type of pancreatic cancer, accounting for 80% of all pancreatic cancer diagnoses.
The treatment paradigm for pancreatic cancer is predominantly composed of chemotherapies, most notably FOLFIRINOX and gemcitabine-based therapies, which are considered to be gold standard for pancreatic cancer. In patients exhibiting genetic mutations, targeted therapies such as Vitrakvi (larotrectinib), Rozlytrek (entrectinib), Poly (ADP-ribose) polymerase (PARP) inhibitor Lynparza (olaparib), and Keytruda (pembrolizumab) are currently included in ....

United States , Ipsen Pharma , Laura Wood , Custom Research , A Key Focus Of Current Clinical Development , Other Drugs In Development , Office Hours Call , Merck Co , Merrimack Pharmaceuticals Baxalta , E St Office Hours Call , Topics Covered , Pancreatic Cancer Market Expected , Novel Tumor Targeting Therapies , Key Focus , Current Clinical , Effective Treatment Options , Unmet Need , Pipeline Agents Demonstrating Increased Overall , Therapies Provide , Brighter Outlook , Incident Cases , Pancreatic Cancer , Year Diagnosed Prevalent Cases , Specific Diagnosed Incident Cases , Eligible Patient Population , Targeting Tumor Immune Evasion ,